Premium
Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas
Author(s) -
Kim YJ,
Cho YE,
Kim YW,
Kim JY,
Lee S,
Park JH
Publication year - 2008
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.2401
Subject(s) - pten , biology , glioma , tumor suppressor gene , cancer research , immunohistochemistry , gene , pathology , gene expression , suppressor , fluorescence in situ hybridization , in situ hybridization , chromosome , carcinogenesis , genetics , immunology , medicine , pi3k/akt/mtor pathway , apoptosis
Glioma tumour‐suppressor candidate region gene 2 ( GLTSCR2 / PICT‐1 ) is localized within the well‐known 1.4 Mb tumour‐suppressive region of chromosome 19q, which is frequently altered in various human tumours, including diffuse gliomas. Aside from its chromosomal localization, several lines of evidence, including PTEN‐phosphorylating and cell‐killing activities, suggests that GLTSCR2 participates in the suppression of tumour growth and development. However, little is known about the biological functions and molecular mechanisms of GLTSCR2 as a tumour suppressor gene. We investigated the pathological significance of GLTSCR2 expression in association with the development and progression of glioblastomas, the most common malignant brain tumour. We used real‐time PCR and western blot analysis to examine the expression levels of GLTSCR2 mRNA and protein in glioblastomas, normal brain tissue and in non‐glial tumour tissue of different origin, and found that GLTSCR2 expression is down‐regulated in glioblastomas. In addition, direct sequencing analysis and fluorescence in situ hybridization clearly demonstrates the presence of genetic alterations, such as a nonsense mutation and deletion, in the GLTSCR2 gene in glioblastomas. Finally, our immunohistochemical study demonstrates that GLTSCR2 is sequentially down‐regulated according to the histological malignant progression of the astrocytic glial tumour. Taken together, our results suggest that GLTSCR2 is involved in astrocytic glioma progression. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.